IIVS, Givaudan & BASF join forces for legalizing a non-animal test
Date: 2018-08-30   Author: Sunil Hebbalkar  Category: #news

IIVS, Givaudan & BASF join forces for legalizing a non-animal test

BASF and Givaudan are reportedly collaborating with IIVS (Institute for In Vitro Sciences), one of acclaimed leaders in in-vitro toxicology. This collaboration is intended to validate an amended technique of skin sensitization reactivity to aid authorities and toxicologists, claim trusted sources.

Reportedly, Givaudan and BASF have come to develop a cutting-edge non-animal testing technique to diagnose a skin related allergic reaction, called sensitization. The test, called Kinetic DPRA or Kinetic Direct Peptide Reactivity Assay, has the potential to predict the potency of a sensitizer. Three such non-animal sensitizer tests have been accepted across the globe.

Erin Hill, President, Institute for In Vitro Sciences, was quoted stating that IIVS is glad about joining forces with Givaudan and BASF over a next-generation technology that has the potential to befittingly transform countless industries and applications. Erin Hill added that the novel collaboration has come into place solely due to the support of the organization’s contributors.

Dr. Andreas Natsch, Head, In Vitro Molecular Screening, Givaudan has been quoted to state that kinetic data can extensively evade risks and help in determining the safe usage level by evaluating the potency of skin sensitizers.

Dr. Robert Landsiedel, Vice President, BASF Experimental Toxicology and Ecology, in this regard, has been quoted to say that the company had been profoundly attracted to investigate potency with minor alterations of the popular and routinely utilized DPRA process. Dr. Landsiedel added that upon validation the Kinetic DPRA technique will completely eradicate the need to use animals for testing chemical potency. He also further mentioned that the organization is rather pleased joining forces with IIVS to prove the validity of this testing method.

For the uninitiated, the validation project is likely to conducted during 2018. The results, if successful, are expected to be furnished to the OECD (Organization for Economic Cooperation and Development) in 2019, claim reliable sources.



About Author


Sunil Hebbalkar

Sunil Hebbalkar

Sunil currently works as an content writer at AlgosOnline. A Post graduate mechanical design engineer by qualification, he worked as an intern at the defense lab for one year in the engine design and development department before switching his professional genre. Foll...

Read More

More from Sunil


Post Recommendents

Fitbit adds blood oxygen level monitoring feature in some devices
Author: Saipriya Iyer

Fitbit- a California based fitness wearables company has reportedly rolled out SpO2 sensors in its devices, enabling users to track their blood oxygen levels. In terms of percentage, between 95% to 100% of blood oxygen...


Modern Health closes $31 Mn funding led by John Doerr & Founders Fund
Author: Pankaj Singh

Modern Health, a startup company based in San Francisco, offering a comprehensive mental health platform for corporate employees, has recently closed a $31 Mn Series B funding round. It was led by Founders Fund and Joh...


Clarify-Leidos form alliance to enhance analytical insights via careC2
Author: Saipriya Iyer

Leidos, a global and FORTUNE® 500 leader in integrating information technology, has recently formed a strategic partnership with Clarify Health Solutions, a leader that delivers advanced health systems and solution...